Replication-competent attenuated chimeric VSV vectors encoding immunogenic SARS-CoV-2 spike proteins
US12311021B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Feb 19, 2021 |
| Grant date | May 27, 2025 |
| Priority date | — |
| Expiry date | Jul 29, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/20034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) vaccines, recombinant vesicular stomatitis virus (VSV) vectors encoding the SARS-CoV-2 spike (S) protein or an immunogenic variant thereof, recombinant replicable VSV particles having a SARS-CoV-2 S protein or an immunogenic variant thereof on the surface of the particles, and immunogenic recombinant proteins comprising a SARS-CoV-2 S protein or a variant thereof. Immunogenic compositions comprising the SARS-CoV-2 vaccines, the recombinant VSV vectors, the recombinant replicable VSV particles and/or the immunogenic recombinant proteins may be used for inducing an immune response to the SARS-CoV-2, preventing infection by the SARS-CoV-2, vaccinating against the SARS-CoV-2 and/or producing adaptive mutants of the recombinant replicable VSV particles.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.